Abstract P3-10-25: The Prognosis of Metaplastic Breast Cancer Patients Compare to Triple-Negative Breast Cancer Patients
| Autor: | Sy Bae, J-M Kim, Sangmin Kim, Je Lee, DH Cho, J-H Choe, SM Hur, MY Koo, Se Kyung Lee, JH Yang, J-H Kim, Seok Jin Nam, Jun Ho Jang, M-Y Choi |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Gynecology
Cancer Research medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Cancer medicine.disease Gastroenterology Metastasis Radiation therapy medicine.anatomical_structure Breast cancer Oncology Internal medicine medicine Adenocarcinoma skin and connective tissue diseases business neoplasms Lymph node Triple-negative breast cancer |
| Zdroj: | Cancer Research. 70:P3-10 |
| ISSN: | 1538-7445 0008-5472 |
| DOI: | 10.1158/0008-5472.sabcs10-p3-10-25 |
| Popis: | Background: Metaplastic breeast cancer (MBC) is a rare, heterogenous cancer characterized by admixture of adenocarcinoma with metaplastic elements, low hormone receptor expression and poor outcome. This study was planned to assess the clinicopathological chacteristics and immunohistochemical findings of MBC compared to invasive ductal carcinoma (IDC) including the triple-negative subtype (TN-IDC). Material and Methods: We retrospectively reviewed the medical records of 47 MBC and 1,346 IDC patients. Two hundred eighteen TN-IDC patients were included in the 1,346 IDC patients. Between 2005 and 2009, these patients were undergone surgical treatment at the Samsung Medical Center. Patients were reviewed clinicopathologic factors, immunohistochemistry of biologic factors such as ER, PR, HER-2, p53, Ki67, cytokeratine (CK) 5/6, epidermal growth factor receptor (EGFR), and treatment modalities (type of operation, use of chemotherapy, radiotherapy and hormone therapy). Result: The MBC patients presented with a larger tumor size (>T1, 66.0% vs. 44.3.%, P = 0.008), lower lymph node involvement (N0, 73.3% vs. 55.6%, P = 0.03), higher histologic (HG) and nuclear grade (NG) (HG3, 70.0% vs. 41.5%, P = 0.001; NG3,82.6% vs. 46.9%, P < 0.001), fewer estrogen receptor (ER), progesterone receptor (PR) and HER2 positivity (ER+, 4.3% vs. 69.2%, P < 0.001; PR+, 6.4% vs. 63.5%, P < 0.001; HER2+, 0% vs. 27.6%, P < 0.001), higher p53, CK5/6 and EGFR expression (p53+, 63.8% vs.38.8%, P < 0.001; CK5/6+, 71.9% vs.21.5%, P < 0.001; EGFR+, 93.9% vs.21.6%, P Discussion: In our result, MBC show poorer clinical outcome than IDC. It is not shown significant difference between MBC and TN-IDC. However, MBC patients with nodal metastasis have poorer prognosis than TN-IDC patients with metastasis despite adjuvant chemotherapy. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P3-10-25. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|